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Abstract
Background: Populations exposed to humanitarian emergencies are particularly vulnerable to mental health
problems, including new onset, relapse and deterioration of psychotic disorders. Inadequate care for this group
may lead to human rights abuses and even premature death. The WHO Mental Health Gap Action Programme
Intervention Guide (mhGAP-IG), and its adaptation for humanitarian settings (mhGAP-HIG), provides guidance for
management of mental health conditions by non-specialised healthcare professionals. However, the
pharmacological treatment of people with non-affective psychosis who do not improve with mhGAP first-line
antipsychotic treatments is not addressed. In order to fill this gap, UNHCR has formulated specific guidance on
the second-line pharmacological treatment of non-affective psychosis in humanitarian, non-specialised settings.
Methods: Following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)
methodology, a group of international experts performed an extensive search and retrieval of evidence on the
basis of four scoping questions. Available data were critically appraised and summarised. Clinical guidance was
produced by integrating this evidence base with context-related feasibility issues, preferences, values and
resource-use considerations.
Results: When first-line treatments recommended by mhGAP (namely haloperidol and chlorpromazine) are
not effective, no other first-generation antipsychotics are likely to provide clinically meaningful improvements.
Risperidone or olanzapine may represent beneficial second-line options. However, if these second-line medications
do not produce clinically significant beneficial effects, there are two possibilities. First, to switch to the alternative
(olanzapine to risperidone or vice versa) or, second, to consider clozapine, provided that specialist supervision and
regular laboratory monitoring are available in the long term. If clinically relevant depressive, cognitive or negative
symptoms occur, the use of a selective serotonin reuptake inhibitor may be considered in addition or as an
alternative to standard psychological interventions.
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Conclusions: Adapting scientific evidence into practical guidance for non-specialised health workers in
humanitarian settings was challenging due to the paucity of relevant evidence as well as the imprecision and
inconsistency of results between studies. Pragmatic outcome evaluation studies from low-resource contexts are
urgently needed. Nonetheless, the UNHCR clinical guidance is based on best available evidence and can help to
address the compelling issue of undertreated, non-affective psychosis in humanitarian settings.
Keywords: Global mental health, Humanitarian settings, Antipsychotics, Non-affective psychosis, Translational
research, Clinical guidance
Background
There has been a dramatic increase in worldwide hu-
manitarian emergency situations in recent years, pro-
voked by forced displacement related to armed conflicts
and persecution as well as to environmental disasters,
including drought, flooding and earthquakes. People in
such humanitarian settings have elevated risks for the
development of mental health issues, which cause add-
itional suffering and constitute major clinical and public
health concerns [1–6]. In humanitarian emergencies,
mental health issues are at risk of being overlooked [7].
In particular, while many efforts have been made to de-
scribe and address stress-related disorders, such as post-
traumatic stress disorder, anxiety and emotional disor-
ders, including depression, far less attention has been
given to the epidemiological characterisation and clinical
management of non-affective psychosis (including
schizophrenia) [8–15]. Thus, there is a major treatment
gap, particularly considering that epidemiological data
suggest that the prevalence of psychotic disorders is
heightened in refugees in comparison with both native
populations and non-refugee migrants [12], and that, in
humanitarian emergencies, people with pre-existing
psychosis are particularly vulnerable to relapse and
deterioration [16–18]. In humanitarian settings, people
with psychotic disorders constitute a significant propor-
tion of the caseload in clinical mental health pro-
grammes, with rates ranging from 8.6% to 41.2% of
overall mental disorders [19–23]. These individuals are
particularly vulnerable to human rights violations, dis-
crimination, social exclusion and even premature death
[24–26].
In the last 10 years, efforts have been made to provide
non-specialised healthcare professionals with easily
accessible tools for managing mental health conditions
of high priority. The World Health Organization
(WHO) and the United Nations High Commissioner for
Refugees (UNHCR) have developed policies and tools to
expand access to mental healthcare to underserved pop-
ulations through the decentralisation of basic mental
healthcare and integration of mental health into primary
care [27, 28]. In particular, the Mental Health Gap
Action Programme Intervention Guide (mhGAP-IG)
[29, 30] and the Mental Health Gap Action Programme
Humanitarian Intervention Guide (mhGAP-HIG) [31]
represent successful examples of this approach. However,
neither mhGAP-IG nor mhGAP-HIG address the man-
agement of people with long-term, disabling mental disor-
ders, particularly non-affective psychosis, who remain
symptomatic after antipsychotic treatment provided
according to mhGAP guidelines. Although the number of
people with treatment-resistant psychosis may be rela-
tively small, the unmet mental health needs of this group
lead to significant social and economic burden for families,
health workers, and the wider community. Furthermore,
for this population, guidance on subsequent pharmaco-
logical options is limited.
In order to fill this gap, UNHCR has recently formu-
lated specific guidance on the pharmacological treatment
of non-affective psychosis in humanitarian non-
specialised settings. This paper anticipates the method-
ology employed to evaluate and summarise the best
available evidence, and reports on how the evidence was
translated into pragmatic guidance for healthcare profes-
sionals. The expected impact of the UNHCR guidance in
humanitarian settings, as well as the potential obstacles
to its effective implementation, are also discussed.
Methods
The Grading of Recommendations, Assessment, Devel-
opment and Evaluation (GRADE) methodology [32]
guided the process from evidence retrieval to the pro-
duction of a pragmatic guidance for health professionals
working in humanitarian settings. A scientific secretariat,
represented by the WHO Collaborating Centre for
Research and Training in Mental Health and Service
Evaluation in Verona, Italy, worked closely with an ad-
visory panel of international experts with in-depth
expertise spanning the fields of clinical psychopharma-
cology, mental health systems and services research in
humanitarian settings, health policy development, health
economics, and implementation science. According to
the GRADE methodology, key scoping questions for this
guidance were formulated on the basis of a shared
process directly involving in-field experts and practi-
tioners, with a strong emphasis on the role of specific
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context variables [33]. These scoping questions guided
evidence retrieval, critical appraisal and interpretation:
(1)In people with non-affective psychosis who do not
improve after treatment with a first-generation anti-
psychotic (FGA), is switching to another FGA effect-
ive and safe?
(2)Are second-generation antipsychotics (SGAs) effect-
ive and safe in people with non-affective psychosis
who do not improve with FGAs used as first-line
treatment?
(3)Which antipsychotic is effective and safe in people
with a diagnosis of treatment-resistant non-affective
psychosis?
(4)Are antidepressant-antipsychotic combinations ef-
fective and safe in people with non-affective psych-
osis who develop depressive, cognitive and negative
symptoms?
In order to address each question, the target popula-
tions, settings, interventions and outcomes of interest
were characterised by employing a Population, Interven-
tion, Comparison, Outcomes framework. In order to
extensively review all available data on the pharmaco-
logical treatments of non-affective psychosis, for each
Population, Intervention, Comparison, Outcomes table we
systematically searched electronic databases (PubMed,
PsychINFO, CINHAL, MEDLINE, Web Of Science Core
Collection, the Cochrane Central Register of Controlled
Trials) to identify the most recent good-quality systematic
review for each intervention of interest. We used the
terms “psychosis OR psychotic OR schizophrenia” in asso-
ciation with (1) specific search filters for systematic re-
views and meta-analyses (http://hiru.mcmaster.ca/hiru/
HIRU_Hedges_MEDLINE_Strategies.aspx#Reviews); (2)
the specific term identifying the subgroup of interest (e.g.
“treatment-resistant”, “negative symptoms”); and (3) the
names of the medications of interest. No language restric-
tions were applied. The last update of the search was per-
formed in January 2017. We included only systematic
reviews and/or meta-analysis of randomised controlled tri-
als including adult patients. When more than one review
provided data for the same outcome, the most recent and
comprehensive review was chosen. When systematic re-
views of randomised trials were not available, we searched
for the most up-to-date and good quality individual ran-
domised trials and observational studies. The scientific
secretariat summarised the results of the included reviews
and assessed their quality by employing the Guideline
Development Tool [34], an online software that helps pro-
duce evidence summaries and healthcare recommenda-
tions according to the GRADE approach. The GRADE
tables produced are available as Additional file 1. On the
basis of evidence summaries, in line with the GRADE
methodology, the panel critically discussed the balance be-
tween the possible clinical advantages and disadvantages
of different treatment options, considering context-related
feasibility issues, costs, ethical issues, values, preferences
and insights from experts working in low-resource set-
tings. This led to the development of the clinical practice
guidance, graphically summarised in Fig. 1. Doses were re-
ported according to licensed doses from the British Na-
tional Formulary [35]. When the licensed dose range was
considered to possibly diverge from that used in common
clinical practice, we employed data from the most updated
systematic reviews or guidelines. Further, additional clin-
ical annotations (including the use of long-acting formula-
tions and relevant insights on the monitoring and
management of adverse events) were derived from the
mhGAP and, if needed, from the most updated inter-
national guidelines and regulatory documents in order to
pragmatically support mental health professionals in rou-
tine practice. These pragmatic annotations will be avail-
able in the final format of the UNHCR guidance.
Additionally, a comprehensive evidence summary report-
ing each step of this process will be made available online
for consultation.
Results
In people with non-affective psychosis who do not im-
prove after treatment with a FGA, is switching to another
FGA effective and safe?
Haloperidol and chlorpromazine were used as the refer-
ence standard, as these medications are the first-line rec-
ommended treatments for patients with non-affective
psychosis in the mhGAP guidelines [29, 36].
We did not find studies of SGA intervention in indi-
viduals who had failed to improve after treatment with
one FGA. Therefore, we included studies conducted in
the general population of people suffering from non-
affective psychosis. This evidence was rated as indirect
(Additional file 1).
According to available evidence, no difference in treat-
ment response was identified between haloperidol and
FGAs as a class, and between haloperidol and the fol-
lowing medications considered individually: chlorpro-
mazine, perphenazine, pimozide, fluphenazine and
trifluoperazine. Haloperidol showed a slightly better
overall acceptability with respect to chlorpromazine, but
caused more movement disorders. Perphenazine and
FGAs as a class did not show benefits compared with
haloperidol in terms of efficacy, acceptability and toler-
ability. Pimozide, fluphenazine and trifluoperazine did
not show benefits over haloperidol in terms of efficacy,
while data on acceptability and tolerability were not
available.
With few exceptions, the GRADE tables showed ‘low’
or ‘very low’ quality for the vast majority of outcomes,
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mostly due to the indirectness of the evidence, as no
data were collected in low-resource settings, and individ-
uals were not included on the basis of being not respon-
sive to haloperidol as first-line treatment. Moreover,
many of the included studies had small sample sizes and
high attrition rates.
In conclusion, the clinical implication was that it is
not possible to identify individual FGAs to recommend
when a first-line treatment with haloperidol proves to be
ineffective. Common clinical practice would suggest
switching to the other most commonly available treat-
ment or chlorpromazine. However, there is still uncer-
tainty and further studies in low-resources/humanitarian
settings may provide relevant insights on this issue.
The therapeutic dose of haloperidol may vary between
2 and 12 mg/day, and a maintenance dose of 4 to 6 mg/
Fig. 1 Flow-chart describing the clinical pathway for the choice of antipsychotics
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day is usually required [35, 37, 38]. For chlorpromazine,
the dose range is from 25 to 1000 mg/day, with a main-
tenance dose of 75 to 300 mg/day [29, 35].
Are SGAs effective and safe in people with non-affective
psychosis who do not improve with FGAs used as first-
line treatment?
Each SGA was compared initially to haloperidol, as the
reference standard of first-line FGAs. SGAs that proved
to be more effective than haloperidol were then com-
pared to each other (head-to-head) in order to identify
possible advantages of one medication over another. We
found no data specifically referring to individuals who
had already failed to improve after treatment with one
FGA. Therefore, studies conducted in the general popu-
lation of people suffering from non-affective psychosis
were used (indirect). Compared to haloperidol, all SGAs
considered individually (with the exception of paliperi-
done, for which no data were available) appeared to
cause less sedation and motor symptoms, and had a bet-
ter overall acceptability profile. Among these medica-
tions, only risperidone and olanzapine showed a more
favourable efficacy profile in comparison with haloperi-
dol. After having compared these two medications head-
to-head, risperidone showed better acceptability and was
associated with less weight gain than olanzapine, while
olanzapine caused less motor symptoms and prolactin
increase.
Indirectness, high attrition rates and imprecise results
(due to small sample sizes) contributed to set the quality
of the evidence to ‘low’ or ‘very low’ for all of the out-
comes of interest. In conclusion, the clinical implication
was that risperidone and olanzapine may be chosen as
second-line treatments as they are both associated with
benefits in comparison with haloperidol in terms of effi-
cacy and overall acceptability in the medium- and long-
term. The level of confidence in this clinical implication
was judged uncertain. The panel pointed out that the
choice between risperidone and olanzapine should be
based on specific patient characteristics and the anti-
psychotic profile, considering that, in general, risperi-
done may have a slightly better overall tolerability and
cause less weight gain compared to olanzapine, while
olanzapine is associated with less motor symptoms and
prolactin increase compared to risperidone. Further, the
choice should take into account availability, affordability
and sustainability of provision in the long term, in rela-
tion to the setting of care. The therapeutic dose of ris-
peridone may vary between 2 and 10 mg/day, and a
maintenance dose of 4 to 6 mg/day is usually required
[35, 39], while the dose of olanzapine may vary between
5 and 20 mg/day, and the maintenance dose required is
usually 10 mg/day [35].
Which individual antipsychotic is effective and safe in
people with a diagnosis of treatment-resistant non-
affective psychosis?
For the purposes of this review, individuals were defined
as treatment-resistant when at least two adequate trials
with different antipsychotics, one of which is a SGA,
proved ineffective. This is an adaptation of the definition
provided by Suzuki et al. [40]. However, considering the
lack of a widely shared consensus on definitions of treat-
ment resistance [41], we included studies of participants
with treatment-resistant psychosis even where this defin-
ition varied. Compared to FGAs, clozapine appeared to
be more effective in terms of clinical improvement, simi-
larly effective in terms of relapse rates, and similarly
acceptable and more tolerable in terms of motor symp-
toms, while blood problems and weight gain were more
frequent in patients taking clozapine. In patients with
treatment-resistant psychosis, risperidone and olanza-
pine appeared to be similarly effective and acceptable in
comparison with clozapine. Risperidone was associated
with less weight gain and sedation, but more motor
symptoms, when compared to olanzapine.
Studies comparing clozapine and olanzapine, as well
as studies comparing clozapine and risperidone, pro-
vided efficacy outcomes of ‘moderate’ quality. By con-
trast, for most of the other outcomes the quality was
‘low’ or ‘very low’ due to indirectness and high attrition
rates.
As a clinical implication, it was concluded that, in
patients not improving after at least two antipsychotics
(one of which is an SGA) administered at adequate dose
and duration, a switch to risperidone or olanzapine (in
people with no previous ineffective exposure to these
medications) or clozapine may be considered. Almost no
evidence exists on other SGAs. The choice to use cloza-
pine must take into account context-related issues,
particularly in relation to safety, given that routine clin-
ical and laboratory monitoring (for the risk of life-
threatening agranulocytosis, but also for other poten-
tially severe adverse events such as seizures and myocar-
ditis [42]) and supervision by a specialist should be
regarded as a fundamental prerequisite.
The therapeutic dose of clozapine may vary between
25 and 900 mg/day, and a maintenance dose of 300 to
600 mg/day is usually required [35, 40, 43].
Are antidepressant-antipsychotic combinations effective
and safe in people with non-affective psychosis who
develop depressive, cognitive and negative symptoms?
Augmentation strategies of antipsychotic treatment with
antidepressants are often considered in the treatment of
depressive, cognitive and negative symptoms in people
with non-affective psychosis. These symptom dimen-
sions are often overlooked and may be associated with
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unfavourable outcomes, such as chronic functional
impairment and higher suicide risk [44–46]. We
therefore retrieved and analysed all available data on
augmentation strategies of antipsychotic treatment with
antidepressants.
Adding antidepressants to antipsychotic treatment ap-
peared to be similarly acceptable in comparison with
antipsychotics alone, and associated with a statistically
relevant benefit on depressive, cognitive and negative
symptoms. A ‘low’ and ‘very low’ quality rating was given
for all outcomes of interest, due to indirectness, high
attrition rates, very small sample sizes and few events
for the majority of included studies, which led to impre-
cise results (Additional file 1).
In conclusion, the clinical implication was that adding
one antidepressant to antipsychotic treatment may be
considered in the case of clinically relevant depressive,
negative or cognitive symptoms. Preference should be
given to selective serotonin reuptake inhibitors, includ-
ing fluoxetine (available widely in generic formulations
and included in the WHO essential list of medicines),
considering their favourable balance between efficacy
and tolerability.
Discussion
Quality shortcomings and implications for research
Translating scientific data on antipsychotics into prag-
matic suggestions to be implemented in humanitarian
settings carries methodological limitations. For this par-
ticular setting, indirectness represented the most press-
ing quality issue. First, none of the studies included in
selected reviews were performed in low-resource settings
or in humanitarian contexts (Additional file 1). Data
were collected in people from stable, high-income,
Western countries, which are often considerably differ-
ent from humanitarian settings with regards to distribu-
tion of risks and mediating factors such as medical
conditions (e.g. dehydration, malnutrition, infectious ill-
nesses), exposure to potentially traumatic events, stabil-
ity of family and social support, and access to
complementary healthcare resources (e.g. psychosocial
support, rehabilitation and a safe medical environment
in case of acute symptoms). Second, studies from high-
income, Western countries may not capture culturally
specific concepts of distress that are relevant to other
countries. In general, it is unclear whether the efficacy of
treatments may differ in contexts characterised by on-
going, chronic adversities [47–49]. Third, even when
supported by sound scientific evidence, some interven-
tions may not be feasible in low-resource settings due to
the need for expensive and/or time-consuming practices
(e.g. laboratory investigations and specialist oversight
needed for clozapine). Fourth, the setting may strongly
affect the burden and impact of side effects and adverse
events. For example, prolactin increase can be managed
with relatively sophisticated interventions in high-
income countries, including laboratory monitoring of
blood prolactin levels, addition of low doses of aripipra-
zole to the current antipsychotic medication, or the
addition of bromocriptine or cabergoline under special-
ist supervision [50]. None of these options is likely to be
feasible and suitable in humanitarian settings. Finally, fo-
cusing on the aim of pragmatically translating available
data into a clinical guidance, we included reviews refer-
ring to populations for which some degree of heterogen-
eity cannot be excluded, as in the case of treatment-
resistant psychosis.
In general, the overall quality of evidence was low for
the majority of outcomes considered. This was due not
only to the setting of care (as in the case of indirectness),
but also resulted from the internal quality of the in-
cluded studies. Most studies included small samples and
had high attrition rates and a short follow-up period,
resulting in both inconsistency of estimates across stud-
ies and imprecise estimates (even after the aggregation
of results from single studies).
For all these reasons, we urgently need to broaden the
evidence base around antipsychotic treatments and in-
clude direct evidence from populations in low- and
middle-income countries and, where possible, from hu-
manitarian settings, instead of merely extrapolating re-
sults from studies in high-income settings [51, 52].
Within the scope of this paper, we see a need for prag-
matic research to establish the cost-effectiveness of vari-
ous SGAs and clozapine.
Given the specific challenges related to conducting
research in humanitarian settings, such studies should
ideally have the form of randomised pragmatic trials fo-
cused on issues such as feasibility and cost-effectiveness
[53, 54]. This review suggests that the introduction of
clozapine as a third step in a treatment protocol could
yield significant benefits. However, there is considerable
uncertainty about the routine use of clozapine in low-
and middle-income countries, mostly because of the risk
of serious, and sometimes life-threatening, side effects
[55, 56].
Implications for practice and policy
In recent years, strong emphasis has been placed on
addressing mental health issues in low-resource and hu-
manitarian contexts in a timely manner, not only to im-
prove the quality of life for people suffering from mental
illness, but also as a necessary step to achieve global
health and development goals [57, 58]. The growing
number of humanitarian and emergency settings, many
of which develop into protracted crises that take years if
not decades to resolve, should prompt global health
researchers to explicitly take these settings into
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consideration. The proposed algorithm (Fig. 1) is aimed
at optimising not only the quality of treatments, but also
the timeliness of care for people with non-affective
psychosis, considering that early intervention is widely
recognised as an essential precondition for achieving
higher response rates and better functioning outcomes
[59]. This algorithm shows relevant differences if com-
pared with current guidelines developed for general set-
tings of care in high-income countries [60–63], which
confirms how, starting from the same evidence base,
clinical decisions can radically differ in relation to
context-related preferences, values, feasibility and cost-
effectiveness considerations.
Among possible obstacles preventing this guidance
from having an effective impact, it should be acknowl-
edged that accurate psychiatric assessment and differen-
tial diagnosis might be particularly challenging for
non-specialised health workers, especially in emergency
and humanitarian contexts. This is generally true for
mental health, but particularly relevant for the area of
psychosis. For example, the onset of non-affective psych-
osis is often preceded by non-specific symptoms, such as
perplexity, obsessive-compulsive manifestations and sub-
threshold mood alterations, whose recognition is chal-
lenging even for trained psychiatrists [64]. In addition, in
contexts with high levels of disorders related to extreme
stress, pre-psychotic stages can be misdiagnosed as
mood disorders. At the same time, severe mood or post-
traumatic disorders with psychotic features can be
mistaken for prodromal psychosis. This is particularly
relevant if we consider that culturally related manifesta-
tions often include mood episodes with psychotic fea-
tures [65–67]. Furthermore, the most appropriate
options for an effective implementation of mental health
recommendations into clinical practice remain unclear
[68], and this issue results particularly challenging for
humanitarian, low-resources settings [69, 70]. Therefore,
although guidance on psychopharmacology can notably
improve the effectiveness and timeliness of interventions
in humanitarian settings, this tool alone cannot be con-
sidered as exhaustive. Sustainable improvements in the
quality of treatments for people with severe mental ill-
ness need to be supported by a broader cultural and
structural change in health systems on multiple levels
[71–73].
Conclusions
Underdiagnosed and undertreated non-affective psych-
osis is a compelling issue for health workers in humani-
tarian and emergency settings. By conducting an
appraisal of the best evidence base, the present UNHCR
guidance attempts to pragmatically address this treat-
ment gap. The adaptation of available scientific evidence
to inform clinical practice in humanitarian settings has
proved particularly challenging mainly due to indirect-
ness of data, which needs to be urgently supplemented
by large and pragmatic in-field clinical research. Hopefully,
the implementation of this pragmatic guidance may notably
improve cost-effectiveness and timeliness of pharmaco-
logical interventions in the context of wide and multilevel
actions towards better practices and policies for people with
psychosis.
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